---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-024720"
form_type: "8-K"
ticker: "ELTP"
cik: "0001053369"
company_name: "ELITE PHARMACEUTICALS INC /NV/"
filed_at: "2024-06-21T23:59:59+00:00"
generated_at: "2026-06-01T02:41:34.251681+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Elite Pharmaceuticals acquires three ANDAs from Nostrum Laboratories for $900k

## Summary
- Acquired ANDAs for generic Norco (hydrocodone/APAP), Percocet (oxycodone/APAP), and Dolophine (methadone) from Nostrum.
- Paid $900,000 cash; also received royalty-free perpetual license for manufacturing technology.
- Asset Purchase Agreement signed June 17, 2024; transaction closed June 21, 2024.

## SEC filing metadata
- accession: 0001493152-24-024720
- form_type: 8-K
- ticker: ELTP
- cik: 0001053369
- company_name: ELITE PHARMACEUTICALS INC /NV/
- filed_at: 2024-06-21T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1053369/000149315224024720/0001493152-24-024720-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1053369/000149315224024720/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-024720
- JSON: https://secwatch.observer/filing/0001493152-24-024720.json
- Plain text: https://secwatch.observer/filing/0001493152-24-024720.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.